Molecular biology of breast cancer metastasis. Inflammatory breast cancer: Clinical syndrome and molecular determinants

Breast Cancer Research

Volumn 2, Issue 6, 2000, Pages 423-429

  Kleer, C G ^a   van Golen, K L ^a   Merajver, S D ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Inflammatory breast cancer; Insulin like growth factor binding proteins; Molecular genetics; RhoC GTPase

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANGIOGENESIS; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL LINE; DISEASE COURSE; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; LYMPH NODE; METASTASIS; MOLECULAR BIOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHENOTYPE; PROGNOSIS; REVIEW; SYNDROME; TUMOR SUPPRESSOR GENE; UNITED STATES;

ANIMALS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYTOKINES; DISEASE-FREE SURVIVAL; ENDOTHELIAL GROWTH FACTORS; ESTROGENS; FEMALE; GENES, P53; HUMANS; INFLAMMATION; LYMPHATIC METASTASIS; LYMPHOKINES; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; PROGESTERONE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034469922     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr89     Document Type: Review

References (49)

1. Inflammatory carcinoma of the breast: A report of twenty-eight cases from the breast clinic of Memorial Hospital
2. Locally advanced breast cancer with inflammatory component: A clinical entity with a poor prognosis
3. Inflammatory carcinoma of the breast
4. Inflammatory carcinoma of the breast
5. Carcinoma of the breast II - Criteria of operability
6. Roentgen therapy alone as the method of treatment of cancer of the breast
7. Results of treating stage III carcinoma of the breast by primary radiation therapy
8. Natural history of survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy
9. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer
10. Multimodal treatment of locoregionally advanced breast cancer
11. Primary chemotherapy in the treatment of inflammatory breast carcinoma: A study of 230 cases from the Institut Gustave-Roussy
12. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer
13. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: The University of Michigan experience
14. Prognosis following slavage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer
15. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy
16. Inflammatory breast cancer: A review
17. Review of known prognostic variables
18. Inflammatory carcinoma of the breast: Results of a combined-modality approach - M.D, Anderson cancer center experience
19. Estrogen receptors in human breast cancer. 1. Methodology and characterization of receptors
20. Biological factors of prognostic significance in locally advanced breast cancer
21. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma
22. Strong association between c-myb and oestrogen-receptor expression in human breast cancer
23. The role of p53 in tumor progression
24. Mutations in the p53 gene occur in diverse human tumour types
25. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
26. Chromosome 17 deletions and p53 gene muations in colorectal carcinoma
27. Two distinct mechanisms alter p52 in breast cancer: Mutation and nuclear exclusion
28. Genetic basis for p53 overexpression in human breast cancer
29. Two distinct mechanism alter p53 in breast cancer: Mutation and nuclear exclusion
30. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma
31. p53 mutations and overexpression in locally advanced breast cancers
32. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype
33. The IGFBP superfamily
34. The GTP-binding Protein Rho
35. Critical role of Rho in cell transformation by oncogenic Ras
36. Rho GTPases and the actin cytoskeleton
37. Rho GTPases control polarity, protrusion, and adhesion during cell movement
38. Overexpression of the RhoC gene correlates with progression of ductal adenocarcinoma of the pancreas
39. Role of insulin-like growth factor binding proteins in controling IGF actions
40. IGF-independent regulation of breast cancer growth by IGF binding proteins
41. Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas
42. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor supressor for prostate cancer
43. Vascular enothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flt 1) and VEGF receptor 3 (Flt 4)
44. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer
45. Molecular cytogenetic analysis of 11 new breast cancer cell lines
46. A novel human xenograft model of inflammatory breast cancer
47. Human breast cancer cell lines as models of growth regulation and disease progression